Octagon Capital Advisors LP

Octagon Capital Advisors LP reported 26 holdings worth US$751M as of Sep 30, 2026 (Form 13F)

As of Sep 30, 2026 · Filed Nov 16, 2026

Octagon Capital Advisors LP reported 26 holdings worth US$751M as of Sep 30, 2026. Largest: Dianthus Therapeutics, Inc., Abivax SA and Definium Therapeutics, Inc. Filed Nov 16, 2026 (Form 13F).

Holdings
26
Value as reported
US$751M

The filing in full

CompanySharesValue as reported% of portfolio
Dianthus Therapeutics, Inc.1.69MUS$149M19.8%
Abivax SA993KUS$98.3M13.1%
Definium Therapeutics, Inc.2.51MUS$95.6M12.7%
Cogent Biosciences, Inc.2.35MUS$75.2M10.0%
ArriVent BioPharma, Inc.2.14MUS$64.8M8.6%
Taysha Gene Therapies, Inc.9.69MUS$47.2M6.3%
Obsidian Therapeutics, Inc.2.41MUS$33.2M4.4%
Kymera Therapeutics, Inc.205KUS$22.9M3.1%
Disc Medicine, Inc.270KUS$17.7M2.4%
Tango Therapeutics, Inc.630KUS$15.7M2.1%
Xenon Pharmaceuticals Inc.420KUS$15.6M2.1%
Adlai Nortye Group Ltd.935KUS$15M2.0%
Mirum Pharmaceuticals, Inc.169KUS$14.5M1.9%
Aktis Oncology, Inc.713KUS$13.9M1.8%
Palisade Bio, Inc.10.3MUS$13.9M1.8%
BioAge Labs, Inc.1.3MUS$9.22M1.2%
Gyre Therapeutics, Inc.954KUS$7M0.93%
DBV Technologies SA574KUS$6.75M0.90%
Ocular Therapeutix, Inc.600KUS$4.6M0.61%
Trevi Therapeutics, Inc.315KUS$4.51M0.60%
Sensei Biotherapeutics, Inc.100KUS$2.97M0.40%
Precision BioSciences, Inc.430KUS$2.69M0.36%
Unicycive Therapeutics, Inc.275KUS$1.29M0.17%
Gossamer Bio, Inc.96,875US$1.15M0.15%
Alumis Inc.0US$00.00%
Context Therapeutics Inc.0US$00.00%
Summit Therapeutics Inc.0US$00.00%

Source

Download original · View original at SEC

Related